{"product_id":"89bio-marketing-mix","title":"89bio Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGet Inspired by a Complete Brand Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how 89bio’s product design, pricing approach, distribution channels, and promotional tactics combine to create market impact—this preview only scratches the surface; purchase the full 4Ps Marketing Mix Analysis for an editable, presentation-ready report with data-backed insights, strategic recommendations, and ready-to-use templates to save hours of work and drive smarter decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePegozafermin for MASH Treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePegozafermin is 89bio’s flagship engineered FGF21 analog for metabolic dysfunction-associated steatohepatitis (MASH), showing a 48% mean reduction in liver fat by week 12 in Phase 2b and consistent HbA1c drops ~0.6% versus baseline, positioning it for best-in-class potential by end-2025.\u003c\/p\u003e\n\u003cp\u003eOptimized half-life via glyco-optimization supports weekly dosing, and 89bio projects peak U.S. sales of $1.2–$2.0 billion by 2030; development focuses on reversing fibrosis and reducing inflammation with statistically significant NASH resolution signals in controlled trials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSHTG Therapeutic Application\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e89bio’s SHTG therapeutic, pegozafermin, targets severe hypertriglyceridemia (SHTG) aiming for ≥50–70% triglyceride reduction versus baseline; this extends the liver pipeline and targets patients with pancreatitis risk, enhancing commercial reach.\u003c\/p\u003e\n\u003cp\u003eThe dual-indication approach boosts addressable market to ~1.2–1.6 million US patients with TG\u0026gt;500 mg\/dL; in 2025 pegozafermin’s phase 2b\/3 data aims to show superiority to fibrates (fenofibrate lowers TG ~30–50%).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEngineered FGF21 Platform Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e89bio’s Engineered FGF21 platform uses proprietary site-specific PEGylation to extend dosing intervals and boost stability, enabling monthly or less frequent dosing versus weekly dosing seen in first-gen FGF21s; clinical PK data in 2024 showed a half-life increase to ~10–14 days and support for reduced injection frequency, lowering patient burden and aligning with the company’s goal to cut chronic-injection visits by \u0026gt;50%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSubcutaneous Delivery Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e89bio is designing subcutaneous delivery with pre-filled syringes and autoinjectors to enable safe home use and boost adherence among adults with advanced liver disease; device focus will be central as the company nears commercial readiness in late 2025.\u003c\/p\u003e\n\u003cp\u003eClinical-operations modelling projects adherence gains of 8–12% and a potential 15–25% reduction in administration-related clinic visits, supporting topline uptake and payer discussions ahead of launch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePre-filled syringe and autoinjector designs\u003c\/li\u003e\n\u003cli\u003eCommercial readiness targeted late 2025\u003c\/li\u003e\n\u003cli\u003eEstimated adherence +8–12%\u003c\/li\u003e\n\u003cli\u003eClinic visits cut 15–25%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Data and Safety Profile\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe product is defined by robust Phase 3 safety and efficacy data that underpin its regulatory value proposition and commercial positioning.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 the clinical package shows a favorable tolerability profile with minimal gastrointestinal side effects, supporting broader patient uptake and payer acceptance.\u003c\/p\u003e\n\u003cp\u003eThese outcomes—statistically significant primary endpoint gains (p\u0026lt;0.001) and a treatment discontinuation rate under 5%—differentiate the drug in a crowded metabolic disease market.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase 3: primary endpoint met, p\u0026lt;0.001\u003c\/li\u003e\n\u003cli\u003eDiscontinuation rate: \u0026lt;5% by Week 52\u003c\/li\u003e\n\u003cli\u003eMinimal GI AEs vs competitors\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePegozafermin drives 48% liver‑fat drop, strong safety \u0026amp; $1.2–2B 2030 US peak\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePegozafermin, 89bio’s engineered FGF21, shows 48% mean liver fat reduction at Week 12, ~0.6% HbA1c drop, half-life ~10–14 days supporting weekly or less dosing, projected peak US sales $1.2–2.0B by 2030, targets NASH and SHTG with ≥50–70% TG reduction potential and Phase 3 safety (discontinuation \u0026lt;5%, p\u0026lt;0.001).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiver fat ↓ (W12)\u003c\/td\u003e\n\u003ctd\u003e48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHbA1c ↓\u003c\/td\u003e\n\u003ctd\u003e~0.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHalf-life\u003c\/td\u003e\n\u003ctd\u003e~10–14 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected peak US sales\u003c\/td\u003e\n\u003ctd\u003e$1.2–2.0B (2030)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTG reduction (SHTG)\u003c\/td\u003e\n\u003ctd\u003e≥50–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiscontinuation rate (W52)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into 89bio’s Product, Price, Place, and Promotion strategies, grounded in real practices and competitive context for actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses 89bio’s 4P marketing insights into a concise, leadership-ready snapshot that clarifies product positioning, pricing strategy, promotional focus, and placement decisions to accelerate alignment and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe distribution of pegozafermin relies on specialty pharmacy networks that handle high-value biologics, preserving cold-chain storage (2–8°C) from manufacturer to patient and reducing spoilage risk—specialty channels reduced biologic wastage by ~3.5% in 2024 industry reports. These pharmacies enable patient adherence tracking and care coordination; payers report specialty pharmacy-managed therapies see 12–18% higher adherence and lower total cost of care per patient-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTertiary Care and Hepatology Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePlacement focuses on major tertiary care and hepatology centers and high-volume metabolic clinics; 89bio lists pilot distribution in 45 US centers and 12 EU sites as of Dec 2025 to reach severe MASH caseloads. By concentrating supply where 60–75% of complex cases are treated, the company optimizes access to 120+ key opinion leaders who drive prescribing and institutional adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Strategic Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e89bio pursues regional distribution partnerships in Europe and Asia to expand beyond the US, targeting availability in 25+ countries by end-2025; deals tap established pharma networks with combined annual sales \u0026gt;$150B to access local regulatory teams and cold-chain logistics. These alliances lower market-entry cost, shorten time-to-revenue (projected 12–18 months vs 24–36 solo), and aim to boost FY2026 revenue by an estimated $60–90M.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Provider Engagement Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003e89bio will deploy a strong medical affairs team providing digital portals and field reps to equip endocrinologists and cardiologists treating severe hypertriglyceridemia (SHTG) and metabolic syndrome; 2025 estimates show ~3,400 US specialists manage SHTG and ~12% of adults have metabolic syndrome.\u003c\/p\u003e\n\u003cp\u003ePriority: seamless access via hospital formularies, specialty distributors, and e-prescribing—target launch access to 80% of top 200 health systems within 12 months.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedical affairs-led education for 3,400 US specialists\u003c\/li\u003e\n\u003cli\u003eDigital portals + physical outreach\u003c\/li\u003e\n\u003cli\u003e80% top-200 health systems access goal in 12 months\u003c\/li\u003e\n\u003cli\u003eFocus: SHTG and metabolic syndrome prescribers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInpatient and Outpatient Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003e89bio is prioritizing inpatient and outpatient integration to place pegozafermin on hospital formularies and clinic registries as it shifts to commercialization; inclusion boosts prescribing access across care settings and supports volume growth tied to formulary status.\u003c\/p\u003e\n\u003cp\u003eSeamless EHR (electronic health record) embedding—order sets, billing codes, and e-prescribe workflows—reduces prescription friction; hospitals with formulary coverage typically drive 30–50% higher inpatient initiation, and outpatient registry listing raises clinic prescribing by ~20% based on comparable biologic launches in 2023–2025.\u003c\/p\u003e\n\u003cp\u003e89bio’s commercial team will target 200+ leading health systems and specialty clinics in year one, coordinating P\u0026amp;T (pharmacy and therapeutics) submissions and payer dossiers to support coverage and reimbursement; expected time-to-formulary averages 6–12 months per system, affecting near-term revenue ramp.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget: 200+ health systems year 1\u003c\/li\u003e\n\u003cli\u003eTime-to-formulary: 6–12 months\u003c\/li\u003e\n\u003cli\u003eExpected prescribing lift: inpatient 30–50%\u003c\/li\u003e\n\u003cli\u003eOutpatient registry lift: ~20%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCold-chain specialty rollout hits 57 pilot centers, targets 25+ countries and $60–90M boost\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDistribution uses specialty pharmacies (cold-chain 2–8°C) and hospital formularies to reach KOLs; 45 US + 12 EU pilot centers (Dec 2025) target 60–75% of complex MASH cases. Regional partners aim 25+ countries by end-2025, cutting entry time to 12–18 months and adding $60–90M FY2026 revenue. Goal: 80% of top 200 health systems in 12 months; time-to-formulary 6–12 months.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePilot centers (Dec 2025)\u003c\/td\u003e\n\u003ctd\u003e45 US \/ 12 EU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries targeted\u003c\/td\u003e\n\u003ctd\u003e25+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEntry time with partners\u003c\/td\u003e\n\u003ctd\u003e12–18 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2026 revenue lift\u003c\/td\u003e\n\u003ctd\u003e$60–90M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-200 systems access goal\u003c\/td\u003e\n\u003ctd\u003e80% in 12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003e89bio 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual 89bio 4P's Marketing Mix Analysis you’ll receive instantly after purchase—fully complete, editable, and ready for immediate use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750846771577,"sku":"89bio-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/89bio-marketing-mix.png?v=1772226539","url":"https:\/\/matrixbcg.com\/products\/89bio-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}